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https://doi.org/10.1016/j.celrep.2018.02.084SUMMARY
Since the discovery of mutations in isocitrate dehy-
drogenase 1 (IDH1) in gliomas and other tumors, sig-
nificant efforts have been made to gain a deeper un-
derstanding of the consequences of this oncogenic
mutation. One aspect of the neomorphic function of
the IDH1 R132H enzyme that has received less atten-
tion is the perturbation of cellular redox homeostasis.
Here, we describe a biosynthetic pathway exhibited
by cells expressing mutant IDH1. By virtue of a
change in cellular redox homeostasis, IDH1-mutated
cells synthesize excess glutamine-derived proline
through enhanced activity of pyrroline 5-carboxylate
reductase 1 (PYCR1), coupled to NADH oxidation.
Enhanced proline biosynthesis partially uncouples
the electron transport chain from tricarboxylic acid
(TCA) cycle activity through the maintenance of a
lower NADH/NAD+ ratio and subsequent reduction
in oxygen consumption. Thus, we have uncovered a
mechanism by which tumor cell survival may be pro-
moted in conditions associated with perturbed redox
homeostasis, as occurs in IDH1-mutated glioma.
INTRODUCTION
Mitochondria constitute the major metabolic hubs of the eukary-
otic cell, coordinating the metabolism of different nutrients to
provide themacromolecular building blocks and energy required
for cell function. Cell phenotype is, therefore, greatly dependentCell R
This is an open access article undon appropriate mitochondrial metabolic activity (Chandel, 2015),
and dysfunction could contribute to or drive disease. Indeed, it
was postulated by Otto Warburg in the early 20th century that
mitochondrial metabolic dysfunction is the origin of cellular
transformation (Warburg, 1956). Although this is now considered
not to be a universal paradigm, the first genetic evidence to sup-
port this concept was uncovered at the turn of the 21st century,
where mutations in members of the mitochondrial succinate
dehydrogenase (SDH) complex were discovered to be founder
lesions in hereditary paragangliomas (Baysal et al., 2000). Since
then, mutations in three mitochondrial enzymes and one
mitochondrial-associated enzyme have been shown to drive
tumorigenesis; SDHA-D, fumarate hydratase (FH), and isocitrate
dehydrogenases 1 and 2 (IDH1 and IDH2, respectively) (Frezza
et al., 2011a).
Mutations in IDH1 are observed in a number of tumor types,
including the majority of low-grade gliomas and secondary glio-
blastomas. The mutation observed is a heterozygous missense
mutation in the codon for arginine 132 (R132), most commonly
to histidine in gliomas R132H, although a number of other rare
substitutions are also found (Yan et al., 2009). This mutation
has been shown to result in a loss and gain of function: while
NADP+-linked oxidation of isocitrate is lost, NADPH-coupled
reduction of a-ketoglutarate is gained, with the resulting produc-
tion of (R)-2-hydroxyglutarate (2HG) (Dang et al., 2009). Some of
the major effects of the often millimolar intracellular concentra-
tions of 2HG on cell phenotype are now known, including epige-
netic changes and alterations in the cellular response to hypoxia
(Losman and Kaelin, 2013).
One aspect of mutant IDH1 biology that has received less
attention is the potential effect of its oncogenic function on
cellular redox homeostasis. Cells expressing mutant IDH1 botheports 22, 3107–3114, March 20, 2018 ª 2018 The Authors. 3107
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
lose a source of NADPH-reducing equivalents and acquire novel
NADPH-coupled a-ketoglutarate-reducing activity (Lewis et al.,
2014). This results in a change in the cellular NADPH:NADP+ ratio
that manifests as an altered glutathione (GSH:GSSG) ratio (Bis-
das et al., 2016), as well as sensitization to oxidative stimuli
(Mohrenz et al., 2013; Shi et al., 2015). However, reducing equiv-
alents are also transferred between the cytosolic and mitochon-
drial pyridine pools, through the use of direct translocation (e.g.,
nicotinamide nucleotide translocator; NNT), or through meta-
bolic cycles such as the malate-aspartate or isocitrate-a-keto-
glutarate shuttles. As such, any perturbation in redox homeo-
stasis elicited by mutations in IDH1 may not be confined to the
cytosol but have implications for tumor growth through altered
regulation of mitochondrial metabolism (Grassian et al., 2014).
Therefore, we sought to investigate whether the mitochondria
of IDH1 R132H-expressing cells compensate for the altered
cytosolic redox state through changes in redox-active metabolic
pathways. We found that IDH1 mutant cells exhibit increased
NADH-coupled pyrroline 5-carboxylate reductase 1 (PYCR1)-
dependent proline synthesis from glutamine, which resulted in
the partial uncoupling of respiration from tricarboxylic acid
(TCA) cycle activity. Furthermore, we found that IDH1 mutant
gliomas exhibit increased PYCR1 expression and that tumoral
2HG concentrations correlated with that of proline, suggesting
that this effect is also observed in glioma patients.
RESULTS
IDH1 Mutation Induces Glutamine-Derived Proline
Synthesis
To investigate the changes in redox-active pathways induced
by the IDH1 R132H mutation, we utilized a human anaplastic
oligodendroglioma (HOG) cell line engineered to express either
wild-type (WT) or mutant (R132H) IDH1 (Reitman et al., 2011)
(Figure S1A). 13C6-glucose or
13C5-glutamine was used as the
carbon source to investigate the effects of mutant IDH1 expres-
sion on mitochondrial redox-dependent metabolism (Figures
1A and 1B). The synthesis of glutamate from glucose, which
occurs through the metabolism of pyruvate in mitochondria,
can be either through NAD+-linked pyruvate dehydrogenase
(PDH) activity or through pyruvate carboxylase (PC), which is
redox neutral. These two activities can be differentially observed
though the production of two isotopomers of glutamate:
13C-[4,5]-glutamate (for PDH) and 13C-[1,2,3]-glutamate (for
PC; Figure 1A). We observed that the distribution of isotopomers
was similar between IDH1 WT and mutant cells, suggesting that
there was little detectable alteration in overall NADH:NAD+ regu-
lation through these pathways (Figure 1C). Similarly, the syn-
thesis of glutamate from glutamine, a single deamidation step,
was also unchanged (Figure 1D). Therefore, we analyzed the
incorporation of 13C from both carbon sources into aspartate,
which includes further redox-active enzymatic steps (a-ketoglu-
tarate and malate dehydrogenases). Again, both the glucose-
derived oxidative isotopomers of aspartate (13C-[1,2]/[3,4]-
aspartate) as well as the glutamine-derived 13C4-aspartate
were unchanged (Figures S1B and S1C).
An alternative, redox-active mitochondrial metabolic pathway
is the synthesis of proline from glutamate, which oxidizes 2 mol3108 Cell Reports 22, 3107–3114, March 20, 2018of NAD(P)H per mole of proline synthesized (Figure 1E). This has
previously been suggested to play a role in the cellular redox
stress response (Krishnan et al., 2008; Lorans and Phang,
1981). Although no change in 13C enrichment into proline was
observed from glucose (Figure 1F), a significantly larger propor-
tion of the proline pool was enriched from glutamine in mutant
IDH1 cells (Figure 1G). As the 13C5 isotopomer of proline is syn-
thesized directly from the 13C5-glutamate isotopomer, the ratio
of the two provides an indication of the contribution of gluta-
mine-derived glutamate to the proline pool. This was significantly
increased in IDH1mutant cells compared to IDH1WT (Figure 1H).
Notably, this was different from the synthesis of glutamate-
derived proline produced from glucose (Figure 1I), despite both
glutamate pools being within the mitochondrial matrix. These
data, therefore, suggest that the IDH1 mutation elicits increased
proline synthesis selectively from glutamine. To determine
whether IDH2 mutant cell lines would also demonstrate a similar
response, we created two cell lines using the WT IDH LN18 gli-
oma as parental, to either express IDH1 R132H or IDH2 R172K
(Figures S1D and S1E). We found that, although the IDH1
R132H-expressing cell line recapitulated the proline synthetic
phenotype observed in the HOG line, the IDH2 R172K cell line
did not (Figures S1F and S1G). This suggests that the metabolic
perturbation is specific to the IDH1 isozyme. Many of the pheno-
types reported in IDH1-mutated cells, including the induction of
cellular transformation, have been shown to be secondary to
the production of 2HG (Losman et al., 2013; Lu et al., 2012).
However, our data using the IDH2 R172K cell line, which also
synthesizes significant 2HG compared to IDH1 R132H-express-
ing lines (Figures S1H and S1I), suggested that the proline syn-
thetic phenotype may be independent of this oncometabolite.
Therefore, we tested whether the observed change in proline
metabolism was, indeed, 2HG independent by incubating IDH1
WT cells with 10mM (R)-2HG for 48 hr prior to metabolite extrac-
tion. 2HG incubation produced intracellular 2HG concentrations
that were intermediate between WT and mutant IDH1-express-
ing cells (Figure 1J). However, no increase in intracellular proline
was observed in these conditions, suggesting that the pheno-
type was unlikely to result from increased intracellular 2HG
but, rather, themetabolic consequences arising from the expres-
sion of mutant IDH1.
It has previously been shown that proline catabolism, which is
also redox active, plays a role in malignant cancer cell phenotype
(Elia et al., 2017). Theenhancedsynthesisofprolineobservedhere
could, therefore, either bepart of a cycle to shuttle reducingequiv-
alents between the cytosol and the mitochondria (Hagedorn and
Phang, 1983) or ameansof oxidizingNADH tobypass the electron
transport chain (ETC). If the latter, then the proline synthesized
must be removed from the cell as mitochondrial PYCR enzymes
are significantly product inhibited (De Ingeniis et al., 2012). There-
fore, we compared the concentrations of 13C5-proline in cell
extracts and the media. Although intracellular concentrations of
13C5-prolinewerenotappreciablydifferent, extracellular
13C5-pro-
line concentrations were significantly higher in the medium from
IDH1 mutant cells compared to WT, consistent with increased
synthesis of proline that was not balanced by catabolism (Fig-
ure 2A). Thiswasobservedeven in thepresenceof concentrations
of exogenous proline found in the peripheral plasma (Figure S1J).
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Figure 1. Increased Proline Synthesis in IDH1 Mutant Cells
(A) Alternative entry points of pyruvate into the TCA cycle and the implications for 13C incorporation into metabolites from 13C6-glucose.
(B) Incorporation of 13C5-glutamine into the TCA cycle.
(C) Incorporation of glucose-derived pyruvate into glutamate shows no difference between WT and IDH1 R132H-expressing cells.
(D) 13C incorporation into glutamate from 13C5-glutamine also shows no significant differences between IDH1 mutant and WT cells.
(E) Diagram showing the synthesis of proline from glutamate, with 2 mol NAD(P)H oxidized per mole of glutamate to proline.
(F) The contribution of glucose carbons to the proline pool is unchanged in cells expressing mutant IDH1.
(G) Glutamine carbons that arise directly from glutamate (without a pass through the TCA cycle) are significantly increased as a proportion of the proline pool.
Absolute values were calculated from 1H-NMR spectra.
(Hand I) In (H),when theproline synthesized fromglutamine is normalized to take into account relative changes in glutamate labeling (m+5proline/m+5glutamate;
gas chromatography-mass spectrometry [GC-MS]), this significance is retained, while (I) 13C-[4,5]-proline arising from 13C-[4,5]-glucose remains unchanged
(HSQC NMR spectra).
(J) IDH1WT cells incubated with 10 mM (R)-2HG elicits an intermediate 2HG intracellular concentration that does not increase proline synthesis (calculated from
1H NMR spectra).
All error bars represent mean ± SEM. Statistical tests used for both (G) and (I): 2-way ANOVA with post hoc test to identify individual significant changes. In
(H) and (I), comparisons were performed using a Mann-Whitney test. *p < 0.05; **p < 0.01; ***p < 0.001; n.s., not significant. aKG, a-ketoglutarate; AcCoA, acetyl
coenzyme A; Asp, aspartate; Cit, citrate; Glu, glutamate; OAA, oxaloacetate; OX, oxidative TCA cycle; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase;
Pro, proline; RC, reductive carboxylation; TCA, tricarboxylic acid.Enhanced Proline Synthesis in IDH1-Mutated Cells Is
Mediated through PYCR1
We therefore examined whether IDH1 mutant cells demon-
strated altered proline biosynthetic enzyme expression. Proline
is synthesized from glutamate in two steps; pyrroline 5-carbox-
ylate (P5C) synthase (encoded by ALDH18A1) followed by either
of two P5C reductases (PYCR1 and PYCR2; Figure 1E). The
expression of all three enzymes was found to be similar between
IDH1 WT and R132H-expressing cell lines at both protein (Fig-
ures 2B and S2A) andmRNA (Figure S2B) levels, further suggest-ing that the altered synthesis of proline observed in IDH1 mutant
cells was through a change in redox regulation. To investigate
the role of PYCR1 and PYCR2 on proline metabolism, we
induced transient knockdown of each PYCR isozyme (Figures
2C and S2C) and assessed the effect on proline synthesis from
glutamine. Although little decrease in the intracellular steady-
state concentration of proline was found in the IDH1 WT cells
with either siPYCR1 or siPYCR2 (Figure 2D), a significant
decrease occurred in IDH1 R132H-expressing cells with both
siPYCR1 and siPYCR2. The effect of PYCR1 was confirmed inCell Reports 22, 3107–3114, March 20, 2018 3109
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Figure 2. Enhanced Proline Synthesis Is through Increased PYCR1 Activity in IDH1 Mutant Cells
(A) The absolute amount of proline synthesized from glutamine (calculated from 1H-NMR spectra) is significantly increased in the medium.
(B) IDH1 mutant cells do not increase proline synthesis through upregulation of the mitochondrial proline biosynthetic enzymes.
(C) Confirmation of knockdown of PYCR1 or PYCR2 in both IDH1 WT and mutant cells.
(D) Intracellular proline is unchanged in IDH1 WT cells after siPYCR1 or siPYCR2 but significantly reduced in IDH1 mutant cells in response to either PYCR1 or
PYCR2 (ion counts per 106 cells).
(E) Incorporation of 13C from glutamine into proline is significantly decreased after siPYCR1 in IDH1 mutant cells (40%) compared to (25%) in IDH1 WT cells.
(F) Neither siPYCR1 or siPYCR2 decreased incorporation of glucose into proline.
All error bars represent mean ± SEM. A 2-way ANOVAwith a post hoc test was used for both (A) and (E). **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant.the LN18 cell model (Figure S2D). These data suggest that the
PYCR1 and PYCR2 are the major proline synthetic enzymes in
IDH1 R132H mutant cells.
Since proline synthesized from glucose was not increased in
IDH1 mutant-expressing cells (Figures 1F–1I), we wondered
whether PYCR1 and PYCR2 are responsible for synthesizing
proline from different carbon sources. We first assessed incor-
poration of 13C from glutamine into proline in the presence of
siPYCR1 or siPYCR2 and found that siPYCR1 resulted in a
reduction in 13C5-proline (Figures 2E and S2E). In contrast,
reduction of neither PYCR isozymes affected proline synthesis
from glucose (Figure 2F), providing evidence for a selective use
of glutamine-derived glutamate as a source of proline in IDH1
R132H-expressing cells.
Increased PYCR1 Expression and Proline Synthesis Is
Observed in IDH1-Mutated Gliomas
It is apparent from studies using IDH1 R132H-expressing cells,
including the above HOG cell model, that although expression
of the mutant enzyme may be stable in culture (Figure S1A),
2HG steady-state concentrations may alter over time (Figure 1J;
Figure S1K) (Reitman et al., 2011). To determine whether the
same phenotype was observable in vivo, we first investigated
the expression of PYCR1 and PYCR2 in low-grade gliomas, in
which IDH1 mutations are commonly observed (Yan et al.,
2009). Expression data from 285 lower grade gliomas available3110 Cell Reports 22, 3107–3114, March 20, 2018through The Cancer Genome Atlas (Cerami et al., 2012; Gao
et al., 2013) were analyzed. We found that expression of
PYCR1, but not PYCR2, was increased in IDH1-mutated tumors
(Figures 3A and 3B). We further investigated PYCR1 expression
in IDH1WT andmutated gliomas and confirmed that tumors with
high 2HG concentrations (Figures S3A and S3B, for examples)
also demonstrated increased expression of PYCR1 (Figures
3C, 3D, and S3C–S3F). Based on this, we directly measured pro-
line and 2HGconcentrations in IDH1-mutated gliomas and found
that the steady-state levels of these metabolites were signifi-
cantly correlated (Figure 3E). This observation adds proline to
a growing list of amino acids, the metabolism of which is altered
in tumors expressing the IDH1 mutation. However, collectively,
the in vitro and in vivo data, therefore, suggest that PYCR1
may play a role in redox regulation in IDH1-mutated gliomas.
Mitochondrial NADH-Oxidizing Activity of PYCR1 Is
Oxygen Sparing
PYCR1 has been reported to have a significantly higher affinity
for NADH compared to NADPH (De Ingeniis et al., 2012),
the former being the major pyridine species within most
mammalian cells. Therefore, we examined the effect of siPYCR1
on overall cellular redox homeostasis using the autofluorescence
of reduced pyridine nucleotides (Frezza et al., 2011b). While
siPYCR1 had no effect on relative pyridine autofluorescence in
IDH1WT cells, it resulted in a significant increase in IDH1mutant
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Figure 3. PYCR1 Expression and Proline Syn-
thesis Is Correlated with Mutant IDH1 Activity
in Gliomas
(A and B) The results shown here are based in
whole or partly upon data generated by The Cancer
Genome Atlas (TCGA) Research Network (http://
cancergenome.nih.gov/). PYCR1 (A) and PYCR2
(B) gene expression data from 60 IDH1 WT and 221
IDH1 R132X low-grade gliomas show that PYCR1 is
significantly increased in IDH1 mutant gliomas.
(C) Immunoblotting for PYCR1 in gliomas suggest
that expression is increased with 2HG levels. Patient
information for each lane is shown in Table S1.
(D) Quantification of immunoblot in (C) showing a
significant upregulation of expression of PYCR1.
(E) Proline concentrations in gliomas correlate with
2HG concentration with an r2 value of 0.7082. Pear-
son r value: 0.842, p < 0.0001. Patient information for
this cohort is shown in Table S2.
All error bars represent mean ± SEM. The Mann-Whit-
ney test was used for statistical tests performed in (A)
and (D). **p < 0.01; ****p < 0.0001; n.s., not significant.
See also Tables S1 and S2.cells (Figures 4A and 4B), suggesting that PYCR1 can play a sig-
nificant role in modulating cellular redox. These data were sup-
ported by direct measurement of the NADH:NAD+ ratio (Figures
4C, S4A, and S4B), confirming that PYCR1 plays a significant
role in determining the NAD+:NADH ratio in IDH1 mutant cells.
To assess whether the altered NADH:NAD+ ratio was a result
of cytosolic or mitochondrial metabolism, the pyruvate:lactate
ratio was assessed as a cytosolic surrogate for NADH:NAD+.
Although the ratio in IDH1 R132H-expressing cells was signifi-
cantly shifted toward NAD+ (i.e., increased pyruvate:lactate
ratio), no change was observed in either background following
PYCR1 knockdown (Figures 4D and S4C). To investigate
whether this alteration in cellular redox homeostasis affects the
antioxidant capacity or oxidative stress in IDH1 mutant cells,
we examined the GSH:GSSG ratio—a readout of the major anti-
oxidant response redox couple—and reactive oxygen species
levels. In both HOG and LN18 cell models, siPYCR1 resulted in
no significant change to either readout (Figures S4D and S4E).
These results suggest that PYCR1 activity in IDH1mutant cells
supports mitochondrial NADH oxidation. Complex I is the major
site of NADHoxidation linked to oxygen consumption and proton
pumping for ATP generation. Inhibition of complex I activity
would be expected to limit proliferation through the restriction
of oxidative TCA cycle activity. Although this was the case in
the IDH1 WT cells, the NADH-oxidizing activity of PYCR1 ap-
peared to act as a ‘‘metabolic bypass’’ of complex I, permitting
continued proliferation in the presence of rotenone (Figure 4E).
To investigate whether this bypass could be induced in IDH1
WT cells by increasing the mitochondrial NADH:NAD+ ratio,
incorporation of 13C5-glutamine into proline was assessed in
the presence and absence of rotenone. IDH1 WT cells treated
with rotenone demonstrated a significant compensatory in-
crease in proline synthesis, with IDH1 mutant cells showing
a smaller increase (Figure 4F). This supports the notion that
PYCR1 activity can be induced by increased mitochondrial
NADH:NAD+ ratios, thereby retaining TCA cycle activity whenETC flux is limiting. These data also suggest that inhibition of
PYCR1 activity may induce a compensatory increase in ETC
activity to maintain cellular anabolism. Respiration in IDH1 WT
and R132H-expressing cells was, therefore, investigated after
siPYCR1. Although little effect was noted in IDH1 WT cells,
siPYCR1 significantly increased oxygen consumption in IDH1
R132H cells (Figures 4G and S4F), confirming this compensatory
mechanism.
The enhanced PYCR1 activity in IDH1 mutant cells would be
expected to support the previously reported finding of continued
oxidative TCA cycle function in limiting oxygen tensions (Grass-
ian et al., 2014),whichwealsonote in this cellmodel, using oxida-
tive synthesis of aspartate as a readout (Figure S4G) (Birsoy et al.,
2015; Sullivan et al., 2015). Our data further imply that increased
PYCR1 activity in IDH1 R132H-mutated cells is likely to support
greater cell proliferation for a given respiratory activity. This
may play a particularly important role in gliomas, which are highly
hypoxic, thereby limiting oxidative TCA cycle activity.
DISCUSSION
Since the discovery of mutations in IDH1 in gliomas and other
tumors, significant strides have been made to better understand
the downstream consequences of this oncogenic mutation.
However, one aspect of the neomorphic function of the IDH1
R132H enzyme that has not garnered enough attention is the
perturbation of cellular redox homeostasis that it elicits.
Through comprehensive investigation of the regulation of cen-
tral carbonmetabolism, we are able to show that glioma cells ex-
pressing mutant IDH1 increase the synthesis of proline through
the activity of PYCR1, a mitochondrial NADH-oxidising enzyme.
Our data suggest that, through the maintenance of a lower
NADH:NAD+ ratio, the redox activity of PYCR1 partially uncou-
ples the TCA cycle from respiration, permitting oxygen-inde-
pendent synthesis of anabolic precursors, such as aspartate
and citrate. This is an important finding, as it has been recentlyCell Reports 22, 3107–3114, March 20, 2018 3111
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Figure 4. PYCR1 Activity in IDH1 Mutant Cells Oxidizes Mitochondrial NADH
(A) NAD(P)H autofluorescence shows that knockdown of PYCR1 results in increased NAD(P)H autofluorescence only in IDH1 mutant cells.
(B) Quantification of (A).
(C) Biochemical quantification of the NADH:NAD+ ratio confirms that PYCR1 activity oxidizes NADH in IDH1 mutant cells.
(D) The pyruvate:lactate ratio in IDH1 WT and mutant cells quantified using GC-MS data shows that, although the ratio is larger in IDH1 mutant cells, siPYCR1
does not alter it.
(E) Sub-maximal concentrations of rotenone inhibit the proliferation of IDH1 WT cells significantly more than IDH1 mutant cells.
(F) Inhibition of complex I results in a significant compensatory increase in glutamine-derived proline synthesis in IDH1 WT cells to a level similar to that of IDH1
mutants.
(G) Knockdown of PYCR1 results in increased respiration only in IDH1 mutant cells.
(H) Schematic showing the mechanism by which enhanced PYCR1 activity permits increased anabolism in IDH1 mutant cells.
All error bars represent mean ± SEM. Statistical analyses where shown: 2-way ANOVA with a post hoc test of the relevant pairs of samples. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001.suggested that a major role of respiration in proliferating cells, in
addition to the production of ATP, is to provide electron accep-
tors for the synthesis of aspartate (Birsoy et al., 2015; Sullivan
et al., 2015). Indeed, this is likely to become increasingly impor-
tant in hypoxic conditions, such as those observed in the tumor
microenvironment, and may explain why oxidative TCA meta-
bolism is increased in IDH1 mutant cells, even when oxygen be-3112 Cell Reports 22, 3107–3114, March 20, 2018comes limiting (Grassian et al., 2014). It is important to note that
the 2HG produced by mutant IDH1 may interfere with cell sur-
vival and proliferation in hypoxia by inhibiting the stabilization
of the transcription factor, hypoxia inducible factor 1 (HIF1) (Koi-
vunen et al., 2012; Tarhonskaya et al., 2014). It is, therefore, not
clear what the overall effect of the IDH1 mutation is on hypoxic
tumor phenotype.
The metabolism of the major carbon sources in cancer cells is
not only used for cellular anabolismbut also tomaintain redox ho-
meostasis—a particularly well-characterized cytosolic example
of this being the NADH-coupled reduction of pyruvate to lactate
by lactate dehydrogenase to sustain glycolysis. The data pre-
sented here suggest that the reduction of glutamate to proline
through PYCR1 may be used as a means of maintaining mito-
chondrial redox homeostasis in hostile environments, such as
oxidative stress and limiting oxygen tensions. Consistent with
this, upregulation of PYCR1 has previously been suggested to
form part of a metabolic transcriptional response to hypoxia in a
number of tumors (Haider et al., 2016). Indeed, proline meta-
bolismmay be frequently dysregulated in cancers, with evidence
suggesting increased synthesis (Filipp et al., 2012; Jain et al.,
2012) and, conversely, catabolism (Elia et al., 2017). It will be
important to deconvolute the regulation of proline activity at
different points of the malignant progression of tumors if novel
therapies are tobedesigned toperturb this aspect ofmetabolism.
In summary, we describe a stress-responsive metabolic
pathway characterized by the synthesis of proline through
PYCR1 to sustain cellular anabolism while sparing oxygen.
This finding is likely to be an important metabolic bypass more
generally, which could be hypothesized to permit enhanced
tumor cell viability in hostile conditions, thereby contributing to
the malignant progression of tumors.
EXPERIMENTAL PROCEDURES
Cell Culture
A previously characterized human anaplastic oligodendroglioma (HOG) was
used for all studies, unless otherwise stated, kindly donated by Professor
Hai Yan (Reitman et al., 2011). The LN18 IDH1 WT, IDH1 R132H-expressing,
and IDH2 R172K-expressing cell lines were made as described in the Supple-
mental Experimental Procedures. Cells were maintained in high-glucose
DMEM supplemented with 10% FBS (Thermo Fisher Scientific, UK) and
2 mM L-glutamine in standard conditions. Knockdown of PYCR1 and
PYCR2 was achieved using ON-TARGETplus pools. Tracing experiments
were performed for 24 hr in basic formulation DMEM supplemented with either
10 mM 13C6 glucose or 2 mM
13C5 glutamine.
Tumor Collection and Analysis
Tumors were collected under an approved institutional study (Huashan
Hospital Ethics Committee, Shanghai, P.R. China), and informed consent
was obtained from each patient under institutional review board protocols.
Cohort information is shown in Tables S1 and S2. Metabolite analyses were
performed as described in the Supplemental Information.
Immunoblotting
Cells were lysed directly into Laemmli buffer and run on denaturing reducing
PAGE before being transferred onto nitrocellulose membrane (GE Healthcare,
UK). After blocking, membranes were incubated with one of the following
antibodies: b-actin (Sigma, A4700, 1:4,000), PYCR1, and PYCR2 (Proteintech,
13108-1-AP, 1:5,000 and 17146-1-AP, 1:1,000, respectively). After washing
and incubation with appropriate horseradish peroxidase (HRP)-linked second-
ary antibody (Cell Signaling), membranes were developed using EZ-ECL
(Biological Industries, UK).
NMR Spectroscopy
Cells washed with ice-cold 0.9% saline solution were extracted in 1:1:1
methanol, water, and chloroform. After shaking and centrifugation, the upper
aqueous phase was collected and dried under vacuum. Samples were re-sus-
pended in 100 mM sodium phosphate buffer (pH 7.0) containing 500 mM
2,2-dimethyl-2-silapentane-5-sulfonate (DSS) and 2 mM imidazole and 10%D2O into 1.7-mm nuclear magnetic resonance (NMR) tubes. 1D
1H-NMR
spectra and 2D 1H,13C-heteronuclear single quantum coherence (HSQC)
spectroscopy NMR spectra were acquired and analyzed as detailed in the
Supplemental Information.
Gas Chromatography-Mass Spectrometry
Cells washed with ice-cold 0.9% saline solution were extracted in 1:1:1
pre-chilled methanol, HPLC-grade water containing 1 mg/mL D6-glutaric
acid (C/D/N isotopes) and chloroform. After shaking and centrifugation, the
upper aqueous phase was collected and evaporated in gas chromatography
(GC) glass vials under vacuum. Details on polar metabolite derivatization,
data acquisition, and analysis can be found in the Supplemental Information.
Redox Measurements
NAD(P)H was excited at l = 351/364 nm, and autofluorescence was captured
at l = 385–470 nm. Carbonyl cyanine m-chlorophenyl hydrazine (CCCP;
20 mM) and rotenone (60 mM) were added to each well to achieve basal and
maximal NAD(P)H autofluorescence, respectively. An NAD:NADH assay
(NAD/NADHGlo Assay; Promega, G9071) was performed as per the manufac-
turer’s protocol.
O2 Consumption Measurements
Oxygen consumption measurements were made using a Clark-type oxygen
electrode (Oxytherm, Hansatech Instruments, Norfolk, UK). For details, see
the Supplemental Information.
Statistical Analysis
Samples sizes, reproducibility, and statistical tests used to analyze the data-
sets are described in the figure legends. Briefly, Mann-Whitney (2 samples)
or 2-way ANOVA (R2 sample groups) was used as appropriate, with
multiple-comparisons post hoc tests as required. Unless otherwise noted,
all experiments are representative of at least three biologically independent
experiments in technical triplicate. All error bars represent mean ± SEM. Sta-
tistical tests were performed using GraphPad Prism v.6: *p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.02.084.
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